MedTrace Logo

Phase 1/2a Study of ANPD001 in Parkinson Disease

NCT06344026 · Status: ENROLLING_BY_INVITATION · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2026-05-14

No results posted yet for this study

Summary

This clinical trial is designed to test the safety and tolerability of injecting ANPD001 cells that will mature into dopamine-producing cells into the brain of participants with Parkinson Disease. All participants will have ANPD001 cells manufactured from their own previously collected cells.

Conditions

  • Parkinson Disease

Interventions

BIOLOGICAL

ANPD001

Biologic: ANPD001 is an experimental product derived from the patient's own skin cells converted to induced pluripotent stem cells. The stem cells were differentiated into precursors for brain cells that produce dopamine.

DEVICE

Custom Device

A custom device to facilitate slow injection of small volumes of investigational drugs (including cell therapies), under MRI guidance

Sponsors & Collaborators

  • California Institute for Regenerative Medicine (CIRM)

    collaborator OTHER

  • Aspen Neuroscience

    lead INDUSTRY

Principal Investigators

  • Revati Shreeniwas, MD, FCCP · Aspen Neuroscience

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-23
Primary Completion
2027-03-30
Completion
2030-04-30
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06344026 on ClinicalTrials.gov